CCR5 status and metastatic progression in colorectal cancer.

Abstract

Multiple reports have highlighted the importance of the local immunological cellular composition (i.e. the density of effector T cells and macrophage polarization state) in predicting clinical outcome in advanced metastatic stage of colorectal cancer. However, in spite of the general association between a high effector T cell density and improved outcome, our recent work has revealed a specific lymphocyte-driven cancer cell-supporting signal. Indeed, lymphocyte-derived CCL5 supports CCR5-positive tumor cell proliferation and thereby fosters tumor growth in metastatic liver lesions. Upon systematic analysis of CCR5 expression by tumor cells using immunohistochemistry, we observed that the intensity of CCR5 increases with primary tumor size and peaks in T4 tumors. In liver metastases however, though CCR5 expression intensity is globally heightened compared to primary tumors, alterations in the expression patterns appear, leading to "patchiness" of the stain. CCR5 patchiness is, therefore, a signature of liver metastases in our cohort (n = 97 specimens) and relates to globally decreased expression intensity, but does not influence the extent of the response to CCR5 inhibitor Maraviroc in patients. Moreover, CCR5 patchiness relates to a poor immune landscape characterized by a low cytotoxic-to-regulatory T cell ratio at the invasive margin and enriched cellular and molecular markers of macrophage M2 polarization. Finally, because higher numbers of PD-1- and CTLA-4-positive cells surround tumors with patchy CCR5 expression, one can speculate that these tumors potentially respond to immune checkpoint blockade. This hypothesis is corroborated by the prolonged disease-free survival and disease-specific survival observed in patients with low gene expression of CCR5 in metastases from two publically available cohorts. These observations highlight the complex role of the CCL5-CCR5 axis in CRC metastatic progression and warrant further investigations.

• Authors: Meggy Suarez-Carmona, Pornpimol Chaorentong, Jakob Nikolas Kather, Rebecca Rothenheber, Azaz Ahmed, Anna Berthel, Anita Heinzelmann, Rodrigo Moraleda, Nektarios A Valous, Zeynep Kosaloglu, Rosa Eurich, Jana Wolf, Silke Grauling-Halama, Michael Hundemer, Felix Lasitschka, Fee Klupp, Christoph Kahlert, Alexis Ulrich, Martin Schneider, Christine Falk, Dirk Jäger, Inka Zoernig, Niels Halama
• Journal: Oncoimmunology (Oncoimmunology) 2019 Vol. 8 Issue 9 Pg. e1626193 ISSN: 2162-4011 [Print] United States
• PMID: 31428524 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)